KSHN001126
/ Kashiv Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 20, 2024
SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of KSHN001126 in Healthy Post-Menopausal Females
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: Shivanka Research, LLC
New P1 trial
March 14, 2023
Preclinical characterization of KSHN001126, a novel, differentiated and steroidal oral selective estrogen receptor degrader (SERD)
(AACR 2023)
- "Fulvestrant (FLV) (Faslodex®) is the only clinically approved steroidal SERD that requires painful intramuscular administration...Whereas Elacestrant demonstrated efficacy only in a subset of the population (ESR1 mutant) with poor gastrointestinal tolerability...Overall, KSHN001126 demonstrated dose-dependent efficacy (wild type and ESR1 mutation), confirming target engagement and mechanistic synergy (CDK4/6-Palbociclib and PI3K-Alpelisib). Furthermore, KSHN001126 demonstrated additive antitumor efficacy when combined with FLV, indicating a potential additional mechanism other than SERD."
Preclinical • Oncology • CDK4 • ER
1 to 2
Of
2
Go to page
1